13F portfolio / Investment manager
Deep Track Capital
David Kroin (chief investment officer)
The firm is based in Greenwich, CT, according to its SEC filings.
Its earliest 13F holdings report on SEC EDGAR was filed in February 2022.
SEC Form ADV lists David E. Kroin as chief investment officer.
The 13F shows long US-listed stock and option positions only. It leaves out short positions, cash, bonds and most non-US holdings.
- Reported 13F value
- $6.8B
- Positions
- 66
- Est. 1-yearEstimate
- —SPY +15.7%
- Est. 3-year, annualizedEstimate
- —SPY +22.8%
As of Jun 30, 2026 · filed Aug 14, 2026
Holdings
18 new · 21 added · 14 trimmed · 13 unchanged · 14 sold out
| 1 | GH on Yahoo Finance (opens in a new tab) | Guardant Health IncCOM | 7.5% | $509M | 3,393,312 | Added +1.6% | $40.98* | $159.15 | +288.3% |
| 2 | IMVT on Yahoo Finance (opens in a new tab) | Immunovant IncCOM | 5.3% | $360M | 9,341,151 | Trimmed -19.0% | $24.95* | $26.54 | +6.4% |
| 3 | GPCR on Yahoo Finance (opens in a new tab) | Structure Therapeutics IncSPONSORED ADS | 3.7% | $254M | 4,740,072 | Added +10.8% | $33.72* | $21.04 | -37.6% |
| 4 | PCVX on Yahoo Finance (opens in a new tab) | Vaxcyte IncCOM | 3.7% | $250M | 4,300,000 | Unchanged | $45.36 | $62.76 | +38.4% |
| 5 | ALNY on Yahoo Finance (opens in a new tab) | Alnylam Pharmaceuticals IncCOM | 3.7% | $248M | 825,000 | New | $301.61 | $233.42 | -22.6% |
| 6 | MANE on Yahoo Finance (opens in a new tab) | Veradermics IncCOMMON STOCK | 3.6% | $246M | 2,000,000 | Added +300.0% | $82.87 | $106.82 | +28.9% |
| 7 | TARS on Yahoo Finance (opens in a new tab) | Tarsus Pharmaceuticals IncCOM | 3.4% | $231M | 3,666,768 | Added +1.9% | $52.66 | $68.53 | +30.1% |
| 8 | — | Nuvalent IncCOM | 3.2% | $220M | 1,783,322 | Added +29.6% | — | — | — |
| 9 | ALKS on Yahoo Finance (opens in a new tab) | Alkermes PLCSHS | 3.1% | $210M | 4,000,000 | Added +11.4% | $31.31 | $40.56 | +29.5% |
| 10 | OCUL on Yahoo Finance (opens in a new tab) | Ocular Therapeutix IncCOM | 2.8% | $193M | 19,686,282 | Unchanged | $7.47 | $6.93 | -7.2% |
| 11 | BMRN on Yahoo Finance (opens in a new tab) | Biomarin Pharmaceutical IncCOM | 2.8% | $189M | 3,307,481 | Added +187.6% | $54.67 | $54.80 | +0.2% |
| 12 | NRIX on Yahoo Finance (opens in a new tab) | Nurix Therapeutics IncCOM | 2.8% | $188M | 7,736,455 | Added +21.9% | $13.94* | $24.86 | +78.4% |
| 13 | ORKA on Yahoo Finance (opens in a new tab) | Oruka Therapeutics IncCOM | 2.7% | $183M | 1,926,000 | Trimmed -5.3% | $15.68 | $71.01 | +352.8% |
| 14 | ALMS on Yahoo Finance (opens in a new tab) | Alumis IncCOM | 2.6% | $179M | 6,348,558 | Trimmed -6.3% | $25.00 | $6.16 | -75.4% |
| 15 | IONS on Yahoo Finance (opens in a new tab) | Ionis Pharmaceuticals IncCOM | 2.6% | $174M | 2,200,000 | Added +12.8% | $45.94* | $43.19 | -6.0% |
| 16 | CMPS on Yahoo Finance (opens in a new tab) | Compass Pathways PLCSPONSORED ADS | 2.5% | $172M | 12,161,496 | Unchanged | $4.99 | $10.91 | +118.8% |
| 17 | VERA on Yahoo Finance (opens in a new tab) | Vera Therapeutics IncCL A | 2.5% | $172M | 4,000,000 | Trimmed -2.6% | $37.89 | $27.72 | -26.8% |
| 18 | AXSM on Yahoo Finance (opens in a new tab) | Axsome Therapeutics Inc.COM | 2.5% | $171M | 700,000 | Trimmed -36.4% | $113.80 | $157.49 | +38.4% |
| 19 | GMAB on Yahoo Finance (opens in a new tab) | Genmab A/SSPONSORED ADS | 2.3% | $155M | 5,650,000 | Added +54.2% | $28.78 | $37.08 | +28.9% |
| 20 | MLTX on Yahoo Finance (opens in a new tab) | Moonlake ImmunotherapeuticsCLASS A ORD | 2.0% | $136M | 6,999,025 | Added +9.2% | $13.56 | $9.52 | -29.8% |
| 21 | COAG on Yahoo Finance (opens in a new tab) | Hemab Therapeutics Hldgs IncCOM SHS | 1.9% | $132M | 3,602,093 | New | $27.59 | $30.25 | +9.6% |
| 22 | TNGX on Yahoo Finance (opens in a new tab) | Tango Therapeutics IncCOM | 1.9% | $131M | 4,200,000 | Added +52.7% | $13.91 | $22.19 | +59.5% |
| 23 | DFTX on Yahoo Finance (opens in a new tab) | Definium Therapeutics IncCOM SHS | 1.9% | $129M | 2,750,000 | Trimmed -8.3% | $16.97 | $32.20 | +89.8% |
| 24 | GRAL on Yahoo Finance (opens in a new tab) | Grail IncCOM | 1.8% | $125M | 1,834,944 | Added +6.5% | $81.30 | $119.57 | +47.1% |
| 25 | BCAX on Yahoo Finance (opens in a new tab) | Bicara Therapeutics IncCOM | 1.8% | $122M | 4,100,000 | Added +0.9% | $19.37 | $16.92 | -12.6% |
| 26 | MAZE on Yahoo Finance (opens in a new tab) | Maze Therapeutics IncCOM | 1.6% | $111M | 3,732,569 | Added +7.3% | $14.22 | $27.24 | +91.6% |
| 27 | CLDX on Yahoo Finance (opens in a new tab) | Celldex Therapeutics Inc NewCOM NEW | 1.6% | $109M | 2,939,151 | Added +128.9% | $29.57 | $27.81 | -6.0% |
| 28 | LBRX on Yahoo Finance (opens in a new tab) | Lb Pharmaceuticals IncCOM SHS | 1.6% | $109M | 3,352,804 | Unchanged | $15.87 | $36.47 | +129.8% |
| 29 | MBX on Yahoo Finance (opens in a new tab) | MBX Biosciences IncCOM | 1.4% | $96M | 1,732,569 | Trimmed -37.2% | $20.10 | $50.44 | +150.9% |
| 30 | GHRS on Yahoo Finance (opens in a new tab) | Gh Research PLCORDINARY SHARES | 1.3% | $90M | 3,333,334 | New | $20.88 | $18.08 | -13.4% |
| 31 | COGT on Yahoo Finance (opens in a new tab) | Cogent Biosciences IncCOM | 1.1% | $77M | 2,000,000 | Added +100.0% | $33.96 | $29.39 | -13.5% |
| 32 | — | Ataibeckley IncCOM SHS | 1.1% | $76M | 14,417,442 | Added +20.1% | — | — | — |
| 33 | UTHR on Yahoo Finance (opens in a new tab) | United Therapeutics Corp DelCOM | 1.0% | $67M | 123,616 | New | $563.19 | $531.44 | -5.6% |
| 34 | AVTX on Yahoo Finance (opens in a new tab) | Avalo Therapeutics IncCOM NEW | 1.0% | $67M | 3,610,000 | New | $15.81 | $11.35 | -28.2% |
| 35 | VRDN on Yahoo Finance (opens in a new tab) | Viridian Therapeutics IncCOM | 1.0% | $66M | 3,592,740 | Added +157.7% | $16.57* | $19.25 | +16.2% |
| 36 | CYTK on Yahoo Finance (opens in a new tab) | Cytokinetics IncCOM NEW | 0.9% | $60M | 700,000 | Trimmed -49.1% | $47.92 | $62.22 | +29.9% |
| 37 | ALT on Yahoo Finance (opens in a new tab) | Altimmune IncCOM NEW | 0.9% | $59M | 19,250,000 | New | $2.99 | $2.22 | -25.7% |
| 38 | PSNL on Yahoo Finance (opens in a new tab) | Personalis IncCOM | 0.8% | $54M | 4,000,000 | Added +33.3% | $8.37 | $15.69 | +87.5% |
| 39 | ACRS on Yahoo Finance (opens in a new tab) | Aclaris Therapeutics IncCOM | 0.7% | $49M | 9,345,000 | Unchanged | $3.37 | $3.32 | -1.8% |
| 40 | CRMD on Yahoo Finance (opens in a new tab) | Cormedix IncCOM | 0.7% | $49M | 6,274,076 | Unchanged | $10.55 | $7.28 | -31.1% |
| 41 | WGS on Yahoo Finance (opens in a new tab) | Genedx Holdings CorpCOM CL A | 0.7% | $48M | 700,000 | New | $56.83 | $64.54 | +13.6% |
| 42 | HROW on Yahoo Finance (opens in a new tab) | Harrow IncCOM | 0.6% | $41M | 969,000 | New | $37.20 | $27.61 | -25.8% |
| 43 | CRVS on Yahoo Finance (opens in a new tab) | Corvus Pharmaceuticals IncCOM | 0.5% | $37M | 2,491,939 | Unchanged | $15.96 | $9.49 | -40.5% |
| 44 | SLDB on Yahoo Finance (opens in a new tab) | Solid Biosciences IncCOM NEW | 0.5% | $36M | 3,565,062 | Unchanged | $6.43 | $5.59 | -13.1% |
| 45 | BEAM on Yahoo Finance (opens in a new tab) | Beam Therapeutics IncCOM | 0.5% | $34M | 1,000,000 | Added +21.8% | $28.19 | $23.26 | -17.5% |
| 46 | DYN on Yahoo Finance (opens in a new tab) | Dyne Therapeutics IncCOM | 0.5% | $33M | 1,500,000 | Trimmed -25.0% | $13.25 | $14.35 | +8.3% |
| 47 | IMMX on Yahoo Finance (opens in a new tab) | Immix Biopharma IncCOM | 0.4% | $29M | 2,775,000 | New | $9.28 | $8.15 | -12.1% |
| 48 | XFOR on Yahoo Finance (opens in a new tab) | X4 Pharmaceuticals IncCOM NEW | 0.4% | $27M | 5,878,757 | Trimmed -7.3% | $3.47 | $2.64 | -23.8% |
| 49 | STTK on Yahoo Finance (opens in a new tab) | Shattuck Labs IncCOM | 0.4% | $26M | 3,706,734 | New | $6.24 | $5.37 | -13.9% |
| 50 | MNKD on Yahoo Finance (opens in a new tab) | Mannkind CorpCOM NEW | 0.4% | $26M | 6,000,000 | New | $3.25 | $3.03 | -6.7% |
| 51 | IPSC on Yahoo Finance (opens in a new tab) | Century Therapeutics IncCOM | 0.3% | $23M | 9,462,645 | Unchanged | $2.10 | $1.42 | -32.2% |
| 52 | GENB on Yahoo Finance (opens in a new tab) | Generate Biomedicines IncCOM SHS | 0.3% | $23M | 1,333,815 | New | $13.62 | $11.94 | -12.4% |
| 53 | VSTM on Yahoo Finance (opens in a new tab) | Verastem IncCOM NEW | 0.3% | $22M | 5,740,850 | Unchanged | $8.91 | $8.79 | -1.4% |
| 54 | KURA on Yahoo Finance (opens in a new tab) | Kura Oncology IncCOM | 0.3% | $22M | 1,978,565 | Trimmed -25.2% | $8.59 | $9.29 | +8.1% |
| 55 | ENTA on Yahoo Finance (opens in a new tab) | Enanta Pharmaceuticals IncCOM | 0.3% | $21M | 1,444,167 | Trimmed -26.2% | $12.70 | $11.21 | -11.7% |
| 56 | NKTR on Yahoo Finance (opens in a new tab) | Nektar TherapeuticsCOM NEW | 0.3% | $21M | 300,000 | New | $73.17 | $36.09 | -50.7% |
| 57 | OLMA on Yahoo Finance (opens in a new tab) | Olema Pharmaceuticals IncCOM | 0.3% | $19M | 1,500,000 | New | $13.40 | $6.53 | -51.3% |
| 58 | KLRA on Yahoo Finance (opens in a new tab) | Kailera Therapeutics IncCOMMON STOCK | 0.2% | $15M | 700,000 | New | $21.98 | $11.49 | -47.7% |
| 59 | KARD on Yahoo Finance (opens in a new tab) | Kardigan IncCOM | 0.2% | $14M | 600,000 | New | $23.12 | $12.91 | -44.2% |
| 60 | ELVN on Yahoo Finance (opens in a new tab) | Enliven Therapeutics IncCOM | 0.2% | $11M | 225,000 | New | $42.45 | $37.16 | -12.5% |
| 61 | PMN on Yahoo Finance (opens in a new tab) | Promis Neurosciences IncCOM SHS | 0.2% | $11M | 835,655 | Unchanged | $14.91 | $8.40 | -43.7% |
| 62 | IMCR on Yahoo Finance (opens in a new tab) | Immunocore Hldgs PLCADS | 0.1% | $10M | 311,218 | Trimmed -83.9% | $31.16 | $30.01 | -3.7% |
| 63 | XNCR on Yahoo Finance (opens in a new tab) | Xencor IncCOM | 0.1% | $10M | 593,551 | New | $12.49 | $22.91 | +83.4% |
| 64 | CNTX on Yahoo Finance (opens in a new tab) | Context Therapeutics IncCOM | 0.1% | $4M | 7,419,355 | Unchanged | $1.72 | $0.26 | -85.0% |
| 65 | IVA on Yahoo Finance (opens in a new tab) | Inventiva SAADS | 0.0% | $3M | 800,000 | Trimmed -34.6% | $5.52 | $2.97 | -46.1% |
| 66 | ALGS on Yahoo Finance (opens in a new tab) | Aligos Therapeutics IncCOM NEW | 0.0% | $3M | 444,110 | Unchanged | $16.71 | $5.06 | -69.7% |
Sold out since Q1 2026
- —Apellis Pharmaceuticals Inc$182M at Q1 2026
- —Centessa Pharmaceuticals PLC$125M at Q1 2026
- BBIO on Yahoo Finance (opens in a new tab)Bridgebio Pharma Inc$62M at Q1 2026
- —Terns Pharmaceuticals Inc$57M at Q1 2026
- GERN on Yahoo Finance (opens in a new tab)Geron Corp$47M at Q1 2026
- ANIP on Yahoo Finance (opens in a new tab)Ani Pharmaceuticals Inc$46M at Q1 2026
- —Soleno Therapeutics Inc$36M at Q1 2026
- —Engene Holdings Inc$30M at Q1 2026
- —Apogee Therapeutics Inc$24M at Q1 2026
- JANX on Yahoo Finance (opens in a new tab)Janux Therapeutics Inc$17M at Q1 2026
- CBIO on Yahoo Finance (opens in a new tab)Crescent Biopharma Inc.$8M at Q1 2026
- LRMR on Yahoo Finance (opens in a new tab)Larimar Therapeutics Inc$7M at Q1 2026
- —Cybin Inc$6M at Q1 2026
- BLLN on Yahoo Finance (opens in a new tab)Billiontoone Inc$4M at Q1 2026
Estimated, from reported holdings
Quarter by quarter
High-conviction buys (new positions at 3% or more of the portfolio) since Q3 2023: 6. Of 4 with six months of history, 50.0% beat the S&P 500 from the filing date.
Source: SEC Form 13F-HR 0001856083-26-000004, compared with the Q1 2026 report. 1 option rows are excluded from weights. Tickers map from CUSIP via OpenFIGI. Estimated returns weight each position’s next-quarter total return (Yahoo Finance adjusted closes) by its quarter-end value and assume no trades. Estimated cost averages daily adjusted closes in each quarter the share count rose, from Q3 2023 onward (* = held at the start of our data). Price is the latest close.
Important information
Form 13F data is delayed. Managers have up to 45 days after each calendar quarter to file, so holdings shown may have changed materially since the report date. 13F reports cover long positions in US-listed equities and certain other securities only; they exclude short positions, most non-US holdings, cash, bonds and private investments, and managers may request confidential treatment for some positions. Options rows are listed in filings but are not counted in the holdings and weights shown here.
Estimated holdings returns, estimated cost and high-conviction results are hypothetical calculations from quarter-end holdings and public prices, assuming no trades between reports. They are not the actual returns or costs of any fund or manager and do not reflect fees, trading, leverage, shorts or cash. Biographies are drawn from cited public sources. This page is for information only and is not individualized investment advice or a recommendation to buy or sell any security. Gulfstream Capital and its clients may hold positions in securities shown.